Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan · Delayed Price · Currency is TWD 5.51
+0.02 (0.36%)
Aug 19, 2026, 12:55 PM CST
Merdury Biopharmaceutical Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 4.96M | 3.93M | 380.45% |
| Dec 31, 2023 | 1.03M | -1.65M | -61.46% |
| Dec 31, 2022 | 2.68M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Orient EuroPharma | 4.59B |
| Maywufa Company | 1.64B |
| TSH Biopharm Corporation | 1.40B |
| Allied Biotech | 922.49M |
| Easywell Biomedicals | 799.94M |
| GeneFerm Biotechnology | 664.94M |
| Tien Liang BioTech | 650.87M |
| Johnson Chemical Pharmaceutical Works | 577.93M |